Short answer
TriSalus Life Sciences, Inc. (TLSI) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Clinical Operations officer Jodi Devlin retiring October 1, 2026.
TriSalus Life Sciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Clinical Operations officer Jodi Devlin retiring October 1, 2026
- Dr. Richard Marshall appointed Chief Medical Officer effective June 29, 2026
- Leadership transition places clinical operations and medical leadership under new executives within four months
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TriSalus Life Sciences, Inc. 8-K filings
Get the next TLSI 8-K as it lands
Follow TLSI for push alerts, or ask the research agent what this filing means.